Legal actions and class-action lawsuits brought against Aurora Cannabis involved serious allegations regarding product safety disclosures and corporate financial communications. A prominent national class-action lawsuit filed in Canada alleged that the enterprise negligently failed to warn consumers, medical patients, and healthcare professionals about the risks of developing Cannabinoid Hyperemesis Syndrome (CHS) linked to regular, long-term use of its cannabis products. Additionally, separate securities class actions alleged that the company issued misleading statements or failed to disclose material operational risks prior to downward financial revisions that impacted share valuations.